According to clinical guidelines (e.g., NCCN guidelines), trastuzumab and pertuzumab combined with chemotherapy are the first-line treatment options for the treatment of HER2-positive breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.